Catheter Treatment Articles & Analysis
16 news found
“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. ...
A joint venture between Genesis MedTech and Shockwave was formed in March of 2021 as a partnership to distribute Shockwave’s products in China and to leverage Genesis MedTech’s Wuxi research and development and production base to accelerate the manufacturing of Shockwave’s products for the local Chinese market. The Shockwave M5 and S4 IVL Catheters, which are ...
The AcQForce Flutter trial was designed to evaluate the safety and efficacy of the AcQBlate FORCE sensing ablation catheter and system in the treatment of right atrial typical flutter. Right atrial flutter occurs when rapidly firing electrical signals cause the muscles in the heart’s upper chamber (atria) to contract quickly, leading to a rapid heartbeat ...
Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, ...
The Shockwave M5+ catheter, which has been in limited launch until today, is specifically designed to decrease IVL treatment time, provide alternative access options, and expand IVL therapy to patients with larger vessel sizes. “Shockwave’s new peripheral catheter offers remarkable improvements that enable efficient and effective ...
You should not become pregnant during treatment with JELMYTO. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO. ...
“The vision for pioneering Pulsed Field Ablation treatment was primarily due to PFA’s ability to have high-impact treatment while preserving healthy tissue. ...
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced successful first-in-human use of ultra-low temperature cryoablation (ULTC) for the treatment of monomorphic VT. ...
CloudCath, developer of a remote monitoring and predictive analytics platform for catheter-based treatments, today announced a collaboration with American Renal Associates (ARA), a leading provider of outpatient dialysis services. ...
(CMI) has been granted “Breakthrough Device Designation” from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the MagicTouch SCB Sirolimus Coated Balloon Catheter, for the treatment of small coronary artery lesions in Coronary Artery Disease (CAD). The proposed indication for use includes “The ...
Food and Drug Administration (FDA) approved Investigational Device Exemption (IDE) study was designed to evaluate the performance and safety of the Surfacer Inside-Out® Access Catheter System (Surfacer System) when used to facilitate central venous access in patients with thoracic central venous obstructions. ...
MONTREAL and WALTHAM, Mass., June16, 2020–The Montreal Heart Institute(MHI) and Thermedical®, a developer of thermal-ablation systemsto treat ventricular arrhythmias, today announced the first ablation performed using the groundbreaking Durablate® retractable needle catheter and degassed saline, which together eliminateover98% of the air bubbles that can lead to ...
FDA for its saline enhanced radiofrequency (SERF) ablation system and Durablate catheter in the treatment of ventricular tachycardia (VT). The system uses a new means of biological heat to precisely deliver ablation therapy to the heart.VT is a leading cause of sudden cardiac death worldwide – an event that kills roughly 325,000 U.S. adults each year. ...
Food and Drug Administration (FDA) 510(k) clearance of its first family of access catheters, designed to deliver interventional treatments during minimally invasive neurovascular procedures for aneurysms, stroke and other brain blood vessel conditions. ...
Intravenous (IV) therapy plays a central role in patient care with as many as 90 percent of hospital patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals are adopting technology to improve the placement, safety, and duration for peripheral IV access. ...
This information will allow our treating physicians to view an image of the patients’ prostate during the procedure, showing the heating effect and associated tissue necrosis resulting from our Cooled ThermoTherapy treatment in real-time.” Maury Taylor, ProUroCare chairman and chief executive officer, commented, “We are excited about working with Urologix, the ...